-
2 days ago | 
insights.citeline.com | Dexter Yan
US Tariff Overhang Weighs on Chinese API ExportsChinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war. Additional US tariffs are still weighing on the Chinese exports of active pharmaceutical ingredients (API). (Shutterstock)
-
1 week ago | 
insights.citeline.com | Dexter Yan
China Signals Restarting IPOs For Unprofitable BiotechsThe China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms. New “growth tier” proposed for Shanghai STAR Market for listing standards for unprofitable firms. • Source: Shutterstock
-
1 week ago | 
insights.citeline.com | Dexter Yan
Henlius CEO Details PD-L1 ADC‘s Path To 1L Mono/Combo TherapyHenlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip. Shanghai Henlius Biotech will mainly tweak the safety profile of its PD-L1-targeting ADC HLX43 in Phase II clincial trials. (Shutterstock)
-
2 weeks ago | 
insights.citeline.com | Dexter Yan
Chinese Biotech VC/PE Fundings Rise But Still Modest LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however. Private investors eye novel mechanisms and incremental innovation in drug development from China as they commit new investment funds • Source: Shutterstock
-
3 weeks ago | 
insights.citeline.com | Dexter Yan
Degron Eyes Deals For Novel Molecular Glue Degrader Assets$1bn+ Takeda Alliance Last Year Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip. Molecular glue degraders, an emerging drug class expected to unlock the therapeutic potential of historically hard-to-drug targets, have made progress by leaps and bounds over the past few years. (Shutterstock)
-
1 month ago | 
insights.citeline.com | Dexter Yan
Strong Data For CARsgen’s CAR-T In Late-Line Gastric CancerSurvival Benefits Demonstrated In the world’s first confirmatory randomized controlled trial of any CAR-T therapies in solid tumors, CARsgen’s satricabtagene autoleucel, a Claudin 18.2-targeting chimeric antigen receptor (CAR) T-cell candidate, reduced the risks of death or disease progression by 63% in certain Chinese patients with gastric or gastroesophageal junction (G/GEJ) cancer.
-
1 month ago | 
insights.citeline.com | Dexter Yan
Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo PushPfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn. 3SBio's bispecific antibody SSGJ-707 meets Pfizer's quest for another immuno-oncology therapy to assess in combination with its in-house ADCs. (Shutterstock)
-
1 month ago | 
insights.citeline.com | Dexter Yan
Hengrui Set For Biggest Biopharma IPO So Far This YearHong Kong Listing To Raise Up To $1.27bnJiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions. Hengrui to gross up to $1.27bn from initial public offering in Hong Kong SAR • Source: Shutterstock: stavklem
-
1 month ago | 
insights.citeline.com | Dexter Yan |Xu Hu
China Biopharma Podcast - 14 May 2025 (Chinese Language)Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage. join or China-based editors Dexter Yan and Xu Hu in their latest Chinese language podcast • Source: Citeline/Shutterstock
-
1 month ago | 
insights.citeline.com | Dexter Yan
Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPFNew Results Released In IPO FilingInSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong. InSilico racing against global competitors for disease-modifying therapy for idiopathic pulmonary fibrosis. • Source: Shutterstock
